Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. Patients who suffer from rare diseases, such as nontuberculous mycobacteria (NTM) lung disease and pulmonary arterial hypertension (PAH), face multiple hurdles in finding effective treatments. Insmed is addressing the critical, unmet needs of these orphan patient populations. The company’s lead product candidate is an inhaled antibiotic that is in late-stage clinical development for serious lung infections caused by NTM. There are currently no approved therapies in the United States or European Union for NTM lung disease. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed. “Patients are at the center of everything we do and each of us brings a personal passion for advancing innovative therapies that can transform the lives of patients with rare diseases around the world.” The company is also developing INS1009, a nebulized treprostinil prodrug for the treatment of PAH. Insmed’s innovative focus is on the convenient dosing regimen, enhanced drug delivery, and lower systemic drug exposure which exemplifies its priority to improve patient comfort and care.
Company Growth (employees)
Type
Public
HQ
Bridgewater, US
Size (employees)
161 (est)
Website
insmed.com
Insmed is headquartered in Bridgewater, US

Key People at Insmed

Kevin P. Tully

Kevin P. Tully

EVP & CFO
Steinar Engelsen

Steinar Engelsen

Member Of The Board Of Directors

Insmed Office Locations

Insmed has offices in Bridgewater, Dublin, London, Amsterdam and in 3 other locations
Bridgewater, US (HQ)
10 Finderne Ave
Frankfurt am Main, DE
49 Mainzer Landstraße
Paris, FR
1 Rue Favart
Utrecht, NL
328 Graadt van Roggenweg
Amsterdam, NL
201 Barbara Strozzilaan
London, GB
207 Regent St

Insmed Data and Metrics

Insmed Financial Metrics

Insmed's revenue was reported to be $11.5 m in FY, 2013
USD

Net income (Q1, 2017)

(37.4 m)

EBIT (Q1, 2017)

(36 m)

Market capitalization (15-Aug-2017)

747.8 m

Cash (31-Mar-2017)

125.8 m
Insmed's current market capitalization is $747.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

11.5 m

Revenue growth, %

(100%)

R&D expense

122.7 m

General and administrative expense

50.7 m

Operating expense total

66.5 m87.4 m117.5 m173.4 m

EBIT

(55 m)(87.4 m)(117.5 m)(173.4 m)

EBIT margin, %

(478%)

Interest expense

2.4 m2.4 m2.9 m(3.5 m)

Pre tax profit

(57.3 m)(89.6 m)(120.2 m)(176.2 m)

Income tax expense

98 k

Net Income

(56.1 m)(79.2 m)(118.2 m)(176.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

14.9 m15.2 m17.2 m18.2 m19.2 m20.5 m23.9 m23.4 m22.3 m

General and administrative expense

7.9 m8.2 m9.5 m9.7 m11 m12.5 m12.3 m13.7 m13.7 m

Operating expense total

22.8 m23.4 m26.7 m28 m30.2 m33.1 m36.1 m37.1 m36 m

EBIT

(22.8 m)(23.4 m)(26.7 m)(28 m)(30.2 m)(33.1 m)(36.1 m)(37.1 m)(36 m)

Interest expense

(595 k)(594 k)(722 k)(718 k)(725 k)(622 k)(624 k)(769 k)(1.5 m)

Pre tax profit

(23.2 m)(24 m)(27.4 m)(28.6 m)(31 m)(33.5 m)(36.6 m)(37.7 m)(37.4 m)

Income tax expense

28 k18 k25 k30 k

Net Income

(37.5 m)(61.5 m)(27.4 m)(56 m)(86.9 m)(33.5 m)(70.1 m)(107.9 m)(37.4 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

113.9 m159.2 m282.9 m162.6 m

Accounts Receivable

39.3 m

Inventories

2.3 m5.5 m5.2 m5.8 m

Current Assets

116.2 m164.7 m288.1 m168.4 m

Total Assets

176.5 m230.9 m356.6 m238 m

Accounts Payable

5.9 m9.2 m7.5 m10.4 m

Total Debt

3.1 m

Current Liabilities

16.5 m19.6 m22.3 m28 m

Total Liabilities

83.5 m

Additional Paid-in Capital

534.6 m656.5 m900 m919.2 m

Retained Earnings

(391.6 m)(470.8 m)(589 m)(765.2 m)

Total Equity

143.3 m186.2 m311.7 m154.5 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.2 x1.2 x1.1 x1.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

82.7 m167.3 m134.6 m335 m311 m252.9 m223.1 m200.5 m125.8 m

Current Assets

86.7 m170.8 m140.2 m342.1 m319.3 m258.5 m229.3 m206.3 m131.6 m

Total Assets

150.1 m235.4 m206.2 m408.5 m385.7 m327.7 m299.7 m276.6 m200.7 m

Accounts Payable

11.4 m8.9 m7.9 m8.7 m10.9 m8.7 m9.4 m8.3 m8.5 m

Current Liabilities

21.8 m21.3 m41.1 m43.1 m46.7 m25.5 m32.3 m23.5 m23.3 m

Additional Paid-in Capital

540.3 m651.9 m662.5 m891.5 m896.1 m904.3 m909 m914 m923.8 m

Retained Earnings

(429.1 m)(453.1 m)(498.1 m)(526.8 m)(557.7 m)(622.5 m)(659.1 m)(696.8 m)(802.7 m)

Total Equity

111.5 m199.3 m164.9 m365.3 m339 m282.5 m250.6 m217.8 m121.7 m

Financial Leverage

1.3 x1.2 x1.3 x1.1 x1.1 x1.2 x1.2 x1.3 x1.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(56.1 m)(79.2 m)(118.2 m)(176.3 m)

Depreciation and Amortization

680 k1.1 m2 m2.4 m

Accounts Receivable

757 k

Accounts Payable

(1.1 m)3.3 m(1.8 m)2.8 m

Cash From Operating Activities

(46.7 m)(64.4 m)(100.7 m)(146.7 m)

Purchases of PP&E

(826 k)(5.4 m)(3.5 m)(4.2 m)

Cash From Investing Activities

1.3 m(4.2 m)

Cash From Financing Activities

68.4 m115.1 m227.8 m30.7 m

Interest Paid

1.8 m1.8 m2.9 m3.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(37.5 m)(61.5 m)(27.4 m)(56 m)(86.9 m)(33.5 m)(70.1 m)(107.9 m)(37.4 m)

Depreciation and Amortization

342 k697 k432 k879 k1.3 m514 k1.1 m1.8 m716 k

Accounts Payable

3.6 m2.5 m(1.4 m)(981 k)1.3 m527 k1.2 m361 k(2 m)

Cash From Operating Activities

(30.6 m)(51.5 m)(24.9 m)(49.1 m)(73.2 m)(29.5 m)(57.8 m)(88.7 m)(36.9 m)

Purchases of PP&E

(1.3 m)(2.2 m)(3 m)(588 k)(2.1 m)(3.4 m)(417 k)

Cash From Investing Activities

(895 k)(1.3 m)(2.2 m)(3 m)(588 k)(2.1 m)(3.4 m)(417 k)

Cash From Financing Activities

277 k108.7 m1.5 m227.1 m227.9 m81 k128 k9.8 m565 k

Interest Paid

930 k1.4 m663 k1.5 m2.2 m975 k1.6 m2.5 m1.3 m

Income Taxes Paid

17 k
Y, 2017

Financial Leverage

1.6 x

Insmed Market Value History

Traffic Overview of Insmed

Insmed Company Life and Culture

You may also be interested in